Drug Type Small molecule drug |
Synonyms HSK 21542, HSK-21542, HSK21542 + [1] |
Target |
Action agonists |
Mechanism κ opioid receptor agonists(Kappa opioid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (13 May 2025), |
RegulationPriority Review (China) |
Molecular FormulaC39H57N7O5 |
InChIKeyVWXDZAZSCZVCPV-YFRBGRBWSA-N |
CAS Registry2269511-95-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Pain, Postoperative | China | 13 May 2025 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uremic pruritus | NDA/BLA | China | 23 Sep 2024 | |
Chronic Kidney Disease-Associated Pruritus | NDA/BLA | China | 26 Jun 2024 | |
Pruritus | Phase 2 | China | 28 Feb 2024 | |
Chemical and Drug Induced Liver Injury | Phase 2 | China | 16 Sep 2021 | |
Hepatitis A | Phase 2 | China | 16 Sep 2021 | |
Liver Diseases, Alcoholic | Phase 2 | China | 16 Sep 2021 | |
Analgesia | Phase 2 | China | 01 Jul 2020 | |
Chronic Kidney Diseases | Phase 1 | China | 10 Oct 2023 | |
Uremia | Phase 1 | China | 15 Jun 2021 | |
Acute Pain | Phase 1 | China | 09 Jan 2020 |
Phase 1 | 6 | [14C]HSK21542 2 μg/0.212 μCi/kg | hqahpzawye(usgglhqcdg) = zrzfetitpt widldhextk (ugzsafuljg ) View more | - | 01 Nov 2023 | ||
Phase 2 | 41 | ezjybtvkwu(nvcljvcqsj) = mwznpepnmx qilpedbduk (rtdruuwdzg ) | Positive | 01 Jan 2023 | |||
ezjybtvkwu(nvcljvcqsj) = xjsszncbox qilpedbduk (rtdruuwdzg ) |